Tarsons Products Limited (IN:TARSONS)
:TARSONS
Want to see IN:TARSONS full AI Analyst Report?
Top Page
Tarsons Products Limited
(TARSONS)
Select Model
Select Model
Rating:53Neutral
Price Target:
₹283.00
▲(22.91% Upside)
Action:Reiterated
Date:06/18/26
The score is held back primarily by deteriorating profitability, rising debt, and persistent negative free cash flow. Technicals are a notable positive with a clear uptrend and supportive momentum, but the very high P/E meaningfully reduces the overall attractiveness.
Positive Factors
Recurring consumables business
Tarsons’ core business supplies frequently replenished lab consumables (pipette tips, tubes, cultureware). That replacement-driven demand creates predictable, high-frequency reorder cycles and customer stickiness across diagnostics, pharma and academia, supporting durable revenue visibility and channel leverage.
Negative Factors
Rising leverage
A sharp increase in debt over multiple years raises solvency and refinancing risk. Higher leverage amplifies earnings volatility, increases fixed interest costs, and reduces strategic flexibility. If earnings or cash flow fail to recover, debt servicing could constrain investment and raise default risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring consumables business
Tarsons’ core business supplies frequently replenished lab consumables (pipette tips, tubes, cultureware). That replacement-driven demand creates predictable, high-frequency reorder cycles and customer stickiness across diagnostics, pharma and academia, supporting durable revenue visibility and channel leverage.
Read all positive factors
Tarsons Products Limited (TARSONS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹13.83B
Dividend Yield0.86%
Average Volume (3M)2.32K
Price to Earnings (P/E)95.9
Beta (1Y)1.01
Revenue Growth7.67%
EPS Growth-51.81%
CountryIN
Employees823
SectorConsumer Defensive
Sector Strength42
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)3.87
Shares Outstanding53,206,280
10 Day Avg. Volume1,556
30 Day Avg. Volume2,322
Financial Highlights & Ratios
PEG Ratio-1.29
Price to Book (P/B)1.51
Price to Sales (P/S)2.27
P/FCF Ratio-134.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)11.7
Revenue Forecast (FY)₹4.88B
Tarsons Products Limited Business Overview & Revenue Model
Company Description
Established in 1983 and headquartered in Kolkata, India, Tarsons Products Limited specializes in the global manufacturing and distribution of plastic laboratory supplies and scientific instruments. The company's diverse product portfolio features ...
How the Company Makes Money
Tarsons makes money primarily by manufacturing and selling laboratory plastic consumables under its own product portfolio to laboratories and institutional customers. Revenue is generated from (1) domestic sales in India through distribution netwo...
Tarsons Products Limited Financial Statement Overview
Summary
Income Statement
48
Neutral
Balance Sheet
55
Neutral
Cash Flow
42
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.02B | 4.23B | 3.92B | 2.96B | 2.83B | 3.01B |
| Gross Profit | 1.93B | 1.12B | 1.35B | 985.42M | 2.18B | 1.49B |
| EBITDA | 1.33B | 1.18B | 1.27B | 1.11B | 1.42B | 1.61B |
| Net Income | 205.67M | 143.22M | 297.70M | 426.40M | 807.14M | 1.01B |
Balance Sheet | ||||||
| Total Assets | 11.64B | 11.86B | 10.80B | 9.72B | 7.26B | 5.44B |
| Cash, Cash Equivalents and Short-Term Investments | 313.56M | 252.56M | 256.52M | 226.11M | 590.58M | 774.42M |
| Total Debt | 3.96B | 3.93B | 3.39B | 2.69B | 1.11B | 216.65M |
| Total Liabilities | 5.37B | 5.51B | 4.50B | 3.59B | 1.56B | 543.96M |
| Stockholders Equity | 6.27B | 6.35B | 6.30B | 6.13B | 5.69B | 4.90B |
Cash Flow | ||||||
| Free Cash Flow | -267.75M | -71.03M | -550.87M | -816.28M | -1.14B | -485.02M |
| Operating Cash Flow | 444.51M | 1.18B | 966.20M | 1.03B | 755.99M | 834.67M |
| Investing Cash Flow | -783.05M | -1.30B | -1.47B | -2.85B | -1.79B | -1.38B |
| Financing Cash Flow | 321.34M | 89.33M | 578.12M | 1.36B | 845.61M | 1.30B |
Tarsons Products Limited Technical Analysis
Positive
230.25
Price Trends
221.05
Positive
207.34
Positive
234.28
Positive
Market Momentum
14.33
Negative
63.29
Neutral
70.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:TARSONS, the sentiment is Positive. The current price of 230.25 is above the 20-day moving average (MA) of 229.64, above the 50-day MA of 221.05, and below the 200-day MA of 234.28, indicating a bullish trend. The MACD of 14.33 indicates Negative momentum. The RSI at 63.29 is Neutral, neither overbought nor oversold. The STOCH value of 70.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:TARSONS.
Tarsons Products Limited Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ₹26.69B | 34.37 | ― | 0.16% | 16.08% | 14.59% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
60 Neutral | ₹6.63B | 104.96 | ― | ― | -1.22% | -52.32% | |
56 Neutral | ₹167.27B | 51.91 | ― | 0.19% | 12.30% | -7.05% | |
53 Neutral | ₹13.83B | 95.94 | ― | 0.86% | 7.67% | -51.81% | |
51 Neutral | ₹24.06B | 90.37 | ― | 0.01% | 178.75% | 2120.65% | |
41 Neutral | ₹1.42B | -8.43 | ― | ― | -45.21% | 37.10% |
* Consumer Defensive Sector Average
IN:TARSONS
Tarsons Products Limited
259.95
-124.35
-32.36%
IN:KREBSBIO
Krebs Biochemicals & Industries Ltd.
65.85
-19.68
-23.01%
IN:POLYMED
Poly Medicure Limited
1,650.30
-536.81
-24.54%
IN:VIMTALABS
Vimta Labs Limited
597.55
144.97
32.03%
IN:ZIMLAB
Zim Laboratories Ltd.
123.85
11.42
10.16%
IN:FISCHER
Fischer Medical Ventures Ltd
37.10
-47.64
-56.22%
Tarsons Products Limited Corporate Events
Tarsons attributes share volume surge to market forces, affirms full regulatory compliance
Jun 18, 2026
Tarsons Products Limited has responded to a query from the National Stock Exchange of India after a significant increase in trading volume of its shares. The company stated that it has fully complied with disclosure requirements under SEBI’s...
Tarsons Schedules Virtual Investor Conference with Choice Broking
Jun 6, 2026
Tarsons Products Limited has informed stock exchanges that its officials will participate in an investor conference hosted by Choice Broking on June 11, 2026, via a virtual group meeting. The company stated that discussions with analysts and insti...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.